Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
WEB1 day ago · FRANKFURT, Sept 20 (Reuters) - Sanofi (SASY.PA) said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French ...
Sanofi wins US approval for multiple myeloma drug in newly
WEB14 hours ago · September 20, 2024 at 12:40 PM. -Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has ...
Sanofi eyes approval after MS therapy slows disease progression …
WEB19 hours ago · Sanofi is eyeing global regulatory approval for tolebrutinib after releasing positive Phase III data in non-relapsing secondary progressive multiple sclerosis (MS),. The results from the HERCULES Phase III trial (NCT04411641) showed that Bruton tyrosine kinase (BTK) inhibitor delayed the time to six-month disability progression by 31% compared to placebo.
Latest Sanofi Press Releases and News | Sanofi
WEBAug 26, 2024 · Stay informed with the latest Sanofi press releases and news updates. Discover new developments in healthcare and pharmaceuticals with Sanofi.
Sanofi pushes ahead with €20bn consumer healthcare spin-off
WEBJun 2, 2024 · The move makes Sanofi the latest Big Pharma company to seek to separate low-margin, consumer businesses from divisions focused on innovative new medicines that offer higher returns.
Sanofi Pipeline Transformation to Accelerate Growth Driven by …
WEBDec 7, 2002 · Sanofi’s R&D will lead to a 50% increase in the number of Phase 3 studies between 2023 and 2025, creating the greatest pipeline momentum in Sanofi’s history. The company’s commitment to R&D will also support an expected 25 mid- to late-stage read-outs and up to 19 regulatory submissions for its pharma assets in the next two years.
Press Room - Sanofi US News
WEBApr 26, 2024 · Sanofi US News. New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases.
Press Room - Sanofi US News
WEBJul 17, 2023 · Under the terms of the global agreement, Sanofi made an upfront payment of €120m, has paid development and regulatory milestones of €55m and will pay up to a further €440m upon achievement of certain regulatory and sales-related milestones.
Press Room - Sanofi US News
WEBUpdated as of October 26, 2023. There has been unprecedented demand for Beyfortus™ (nirsevimab-alip). For the first time in history, health care providers are able to help protect an extraordinary number of infants against respiratory syncytial virus (RSV) disease.
Sanofi Says Tolebrutinib Drug Delayed Progressive MS by 31% - U.S. News
WEB1 day ago · US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. ... Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening ...
Skip to content